IQV:NYE-IQVIA Holdings Inc (USD)

COMMON STOCK | Diagnostics & Research |

Last Closing

USD 199.99

Change

+0.88 (+0.44)%

Market Cap

USD 36.13B

Volume

0.40M

Analyst Target

USD 184.17
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-24 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
DHR Danaher Corporation

+1.59 (+0.69%)

USD 165.08B
A Agilent Technologies Inc

+1.50 (+1.11%)

USD 40.09B
LH Laboratory Corporation of Amer..

+1.65 (+0.72%)

USD 19.12B
DGX Quest Diagnostics Incorporated

+0.48 (+0.31%)

USD 17.09B
QGEN Qiagen NV

+0.24 (+0.54%)

USD 10.26B
CRL Charles River Laboratories

+0.90 (+0.49%)

USD 9.50B
VNRX Volitionrx Ltd

+0.04 (+6.56%)

USD 0.06B
ENZ Enzo Biochem Inc

-0.01 (-1.90%)

USD 0.04B
TMO Thermo Fisher Scientific Inc

+3.69 (+0.70%)

N/A
MTD Mettler-Toledo International I..

+11.91 (+0.96%)

N/A

ETFs Containing IQV

EKG First Trust Nasdaq Lux Di.. 5.95 % 0.00 %

+0.09 (+0.50%)

USD 2.66M
BBH VanEck Biotech ETF 0.00 % 0.35 %

+0.65 (+0.50%)

USD 0.42B
GNRX 0.00 % 0.55 %

N/A

N/A
IBB iShares Biotechnology ETF 0.00 % 0.47 %

+0.34 (+0.50%)

USD 6.91B
PBI Pitney Bowes Inc 0.00 % 0.79 %

+0.09 (+0.50%)

USD 1.31B
HIG:CA Global Healthcare Income .. 0.00 % 1.02 %

+0.01 (+0.50%)

CAD 0.05B
VNMC 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -13.57% 23% F 16% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -13.57% 23% F 15% F
Trailing 12 Months  
Capital Gain -13.44% 23% F 16% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -13.44% 23% F 14% F
Trailing 5 Years  
Capital Gain 29.75% 33% F 66% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 29.75% 33% F 56% F
Average Annual (5 Year Horizon)  
Capital Gain 14.40% 92% A 74% C
Dividend Return 14.40% 77% C+ 70% C-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 29.24% 54% F 37% F
Risk Adjusted Return 49.27% 77% C+ 64% D
Market Capitalization 36.13B 78% C+ 94% A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.